Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Fisher Scientific

This article was originally published in The Gray Sheet

Executive Summary

Fisher Scientific: Laboratory instrument firm is evaluating an unsolicited acquisition offer from Trinity I Fund L.P., an investment group associated with members of the Bass family of Texas, the company announces June 5. Trinity, a minority Fisher shareholder, made the offer at a June 4 meeting with Fisher's board of directors. Hampton, New Hampshire-based Fisher says it will respond to the proposal after reviewing it with financial advisors Lazard Freres and Salomon Brothers and legal advisors Wachtell, Lipton, Rosen & Katz. Fisher stock, which had fallen sharply in early May due to lower-than-expected first quarter results, rose 7-1/2 points on the news to close June 5 at 45-3/8. However, Standard & Poor's places its ratings for Fisher on "CreditWatch with negative implications," citing "the potential for weakened credit protection measures associated with an acquisition, including possible defensive tactics"...

You may also be interested in...

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts